Should I buy or sell Akari Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AKTX shares. View AKTX analyst ratings or view top-rated stocks .

What is Akari Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 12 month price objectives for Akari Therapeutics' stock. Their AKTX share price targets range from $30.00 to $30.00. On average, they anticipate the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 927.4% from the stock's current price. View analysts price targets for AKTX or view top-rated stocks among Wall Street analysts .

How have AKTX shares performed in 2023?

Akari Therapeutics' stock was trading at $9.3980 on January 1st, 2023. Since then, AKTX stock has decreased by 68.9% and is now trading at $2.92. View the best growth stocks for 2023 here .

Are investors shorting Akari Therapeutics?

Akari Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 11,200 shares, a drop of 36.0% from the October 31st total of 17,500 shares. Based on an average trading volume of 15,200 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.2% of the shares of the company are short sold. View Akari Therapeutics' Short Interest .

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) posted its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.80) by $5.00.

When did Akari Therapeutics' stock split?

Akari Therapeutics shares reverse split before market open on Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Akari Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , TherapeuticsMD (TXMD) , Biocept (BIOC) , OPKO Health (OPK) , Anavex Life Sciences (AVXL) , Rigel Pharmaceuticals (RIGL) , Teva Pharmaceutical Industries (TEVA) , Vascular Biogenics (VBLT) and Heat Biologics (HTBX) .

Who are Akari Therapeutics' major shareholders?

Akari Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (3.15%). View institutional ownership trends .

How do I buy shares of Akari Therapeutics?

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Akari Therapeutics Stock Price, News & Analysis (NASDAQ:AKTX)

$2.92

+0.01 (+0.34%)

(As of 11/28/2023 ET)

Compare

Today's Range: $2.85
▼
$2.92
50-Day Range: $2.91
▼
$4.13
52-Week Range: $2.81
▼
$12.00

Volume: 7,028 shs
Average Volume: 20,766 shs
Market Capitalization: $16.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $30.00

Akari Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 927.4% Upside
$30.00 Price Target
Short Interest: Healthy
0.22% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.58
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

440th out of 949 stocks

Pharmaceutical Preparations Industry

199th out of 434 stocks

3.5

Analyst's Opinion

Consensus Rating
Akari Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $30.00, Akari Therapeutics has a forecasted upside of 927.4% from its current price of $2.92.
Amount of Analyst Coverage
Akari Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.22% of the float of Akari Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Akari Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Akari Therapeutics has recently decreased by 36.00%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Akari Therapeutics does not currently pay a dividend.
Dividend Growth
Akari Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AKTX.

2.0

News and Social Media Coverage

News Sentiment
Akari Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Akari Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Akari Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Akari Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
61.80% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Price to Book Value per Share Ratio
Akari Therapeutics has a P/B Ratio of 6.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Akari Therapeutics Stock (NASDAQ:AKTX)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

AKTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AKTX Stock News Headlines

November 28, 2023 | sg.finance.yahoo.com

Akari Therapeutics, Plc (CLA.F)

November 24, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Climb Higher Friday

November 28, 2023 | RYSE INC. (Ad)

Secure your stake in the Smart Home industry.

Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.

November 24, 2023 | americanbankingnews.com

Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.com

November 24, 2023 | americanbankingnews.com

Akari Therapeutics (NASDAQ:AKTX) Stock Price Passes Below 200 Day Moving Average of $3.64

November 16, 2023 | finance.yahoo.com

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

November 14, 2023 | msn.com

Travel, Pharma Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday

November 6, 2023 | finance.yahoo.com

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

November 28, 2023 | RYSE INC. (Ad)

Secure your stake in the Smart Home industry.

Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.

October 3, 2023 | finance.yahoo.com

Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now

September 29, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

September 29, 2023 | finance.yahoo.com

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

September 27, 2023 | finance.yahoo.com

Akari Therapeutics to Present at Emerging Growth Conference

September 21, 2023 | finance.yahoo.com

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

September 19, 2023 | finance.yahoo.com

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

September 5, 2023 | finance.yahoo.com

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

August 31, 2023 | msn.com

Akari Therapeutics Plc - ADR (AKTX) Price Target Increased by 1900.00% to 56.10

August 21, 2023 | finance.yahoo.com

British pharma opens U.S. headquarters in Boston

August 18, 2023 | finance.yahoo.com

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

August 17, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Announces ADS Ratio Change

August 15, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics, Plc Announces ADS Ratio Change

August 15, 2023 | msn.com

Akari Therapeutics announces ADS ratio change

August 15, 2023 | finance.yahoo.com

Akari Therapeutics, Plc Announces ADS Ratio Change

August 2, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

August 2, 2023 | finance.yahoo.com

Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

July 27, 2023 | finance.yahoo.com

Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

July 19, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer

See More Headlines

Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/31/2020
Today: 11/28/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AKTX
CUSIP: N/A
CIK: 1541157
Web: www.akaritx.com
Phone: 442080040261
Fax: 646-843-9352
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $30.00
High Stock Price Target: $30.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +934.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.56
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.48 per share
Price / Book: 6.04

Miscellaneous

Outstanding Shares: 5,650,000
Free Float: 2,159,000
Market Cap: $16.39 million
Optionable: Not Optionable
Beta: 1.22

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Ms. Rachelle Suzanne Jacques (Age 52)
President, CEO & Director
Comp: $1.38M
Ms. Wendy F. DiCicco CPA (Age 56)
Interim Chief Financial Officer
Ms. Melissa Bradford-Klug (Age 53)
Chief Operating Officer
Dr. Miles Nunn (Age 54)
Chief Scientific Officer
Dr. John F. Neylan III (Age 70)
M.D., Executive VP & Chief Medical Officer
Ms. Beth-Anne Lang
Senior Vice President of Regulatory Affairs
Annie Mack
Financial Controller

Key Competitors

View All Competitors

Institutional Ownership

Sabby Management LLC
Sold 7,214,040 shares on 11/15/2023
Ownership: 3.152%

View All Institutional Transactions

AKTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Akari Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AKTX shares.
View AKTX analyst ratings or view top-rated stocks.
What is Akari Therapeutics' stock price target for 2024?: 1 Wall Street research analysts have issued 12 month price objectives for Akari Therapeutics' stock. Their AKTX share price targets range from $30.00 to $30.00. On average, they anticipate the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 927.4% from the stock's current price.
View analysts price targets for AKTX or view top-rated stocks among Wall Street analysts.
How have AKTX shares performed in 2023?: Akari Therapeutics' stock was trading at $9.3980 on January 1st, 2023. Since then, AKTX stock has decreased by 68.9% and is now trading at $2.92.
View the best growth stocks for 2023 here.
Are investors shorting Akari Therapeutics?: Akari Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 11,200 shares, a drop of 36.0% from the October 31st total of 17,500 shares. Based on an average trading volume of 15,200 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.2% of the shares of the company are short sold.
View Akari Therapeutics' Short Interest.
How were Akari Therapeutics' earnings last quarter?: Akari Therapeutics, Plc (NASDAQ:AKTX) posted its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.80) by $5.00.

When did Akari Therapeutics' stock split?: Akari Therapeutics shares reverse split before market open on Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Akari Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), Vascular Biogenics (VBLT) and Heat Biologics (HTBX).
Who are Akari Therapeutics' major shareholders?: Akari Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (3.15%).
View institutional ownership trends.
How do I buy shares of Akari Therapeutics?: Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AKTX) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial